Unraveling the Potential Therapeutic Targets and Biomarkers of IGKV1D-33

Target Name: IGKV1D-33

NCBI ID: G28896

Other Name(s): immunoglobulin kappa variable 1D-33 | IGKV1D33 | O8 | Immunoglobulin kappa variable 1D-33

Unraveling the Potential Therapeutic Targets and Biomarkers of IGKV1D-33

Introduction

IGKV1D-33, a 19-kDa immunoglobulin kappa variable chain, is a key regulator of B cell development and function. It is expressed in a variety of tissues and cell types, including placenta, fetal liver, thymus, spleen, and peripheral tissues. IGKV1D-33 has been implicated in the development and maintenance of autoimmune diseases, as well as cancer. As such, it is a promising target for new therapeutic interventions. In this article, we will explore the potential therapeutic targets and biomarkers of IGKV1D-33.

Targets of IGKV1D-33

IGKV1D-33 has been predicted to interact with various molecules, including nuclear factor of activated T cells (NFAT), heat shock factor 7 (HSF7), and the transcription factor, coregulator, and activator of transcription (CREAT). NFAT is a transcription factor factor, which regulates the expression of genes involved in cell signaling pathways, including cell proliferation and differentiation. HSF7 is a non-coding RNA molecule that has been shown to play a role in the regulation of gene expression. CREAT is a transcription factor that regulates the expression of genes involved in cell signaling pathways.

IGKV1D-33 has also been predicted to interact with various protein molecules, including the cytokine, interleukin-1 (IL-1), and the chemokine, chemokine-like protein 1 (CXP-1). These proteins are involved in the regulation of immune responses and cell signaling pathways.

Biomarkers of IGKV1D-33

IGKV1D-33 has been shown to play a role in the development and progression of various diseases, including autoimmune diseases and cancer. There are several biomarkers that have been identified that are associated with IGKV1D-33.

One of the most well-known biomarkers associated with IGKV1D-33 is the development of autoimmune diseases, such as rheumatoid arthritis (RA), lupus, and multiple sclerosis (MS). IGKV1D-33 has been shown to be involved in the regulation of immune cell function and the development of autoantibodies.

IGKV1D-33 has also been shown to be involved in the development and progression of cancer. For instance, studies have shown that IGKV1D-33 is involved in the regulation of the development and progression of various types of cancer, including breast, lung, and ovarian cancer.

Conclusion

In conclusion, IGKV1D-33 is a promising target for new therapeutic interventions due to its involvement in the regulation of B cell development and function, as well as its involvement in the development and progression of autoimmune diseases and cancer. The potential therapeutic targets and biomarkers of IGKV1D-33 will continue to be investigated to develop new treatments for a variety of diseases.

Protein Name: Immunoglobulin Kappa Variable 1D-33

Functions: V region of the variable domain of immunoglobulin light chains that participates in the antigen recognition (PubMed:24600447). Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed:20176268, PubMed:22158414). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed:20176268, PubMed:17576170)

More Common Targets